Search clinical trials for: BioChaperone human insulin

Total 6246 results

Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

Healthy | Diabetes

Germany
Eli Lilly and Company

Completed

A Study for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Brazil, Canada, Mexico, India, Australia, China, Korea, Republic of
Joslin Diabetes Center
Novo Nordisk A/S

Terminated

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

Diabetes
Novo Nordisk A/S

Completed

Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes (EXPECT)

Diabetes | Diabetes Mellitus, Type 1

Israel, Italy, Russian Federation, United Kingdom, Denmark, Austria, Serbia, Canada, Croatia, Australia, Greece, Ireland, Brazil, Spain, Argentina
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (ONWARDS 6)

Diabetes Mellitus, Type 1

United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Ain Shams University

Not yet recruiting

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

Critical Illness | Insulin | Glycemic Control
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Diabetes Mellitus, Type 2

Poland, United States, Croatia, Spain, Slovakia, Germany, Hungary
Novo Nordisk A/S

Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Italy, Mexico, Russian Federation, United Kingdom, Spain, Malaysia, Croatia, Greece, Korea, Republic of, Japan, South Africa, Algeria, Thailand, Argentina, Brazil, Canada, Romania
Novo Nordisk A/S

Completed

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, Japan, Malaysia, Taiwan, Thailand, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Puerto Rico, Slovakia, Canada, South Africa, United Kingdom, Czech Republic
Novo Nordisk A/S

Completed

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™) (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States
Eli Lilly and Company

Completed

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) (AWARD-7)

Type 2 Diabetes | Chronic Kidney Disease

Mexico, United States, Hungary, Ukraine, Brazil, Spain, Romania, South Africa, Poland
Novo Nordisk A/S

Completed

Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents

Diabetes | Diabetes Mellitus, Type 1

United States
Sanofi

Completed

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

Diabetes Mellitus, Type 1

Belarus
Sanofi

Completed

Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Hadassah Medical Organization

Unknown

Cystic Fibrosis (CF) Exacerbation and Insulin Treatment

Cystic Fibrosis | Impaired Glucose Tolerance | Pulmonary Exacerbation

Israel
Fundación Pública Andaluza para la Investigación...

Completed

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (INEOX)

Type 1 Diabetes Mellitus

Spain
Medical University of Graz

Completed

Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (HUCKEPACK2)

Type 2 Diabetes

Austria
Sanofi

Completed

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)

Diabetes Mellitus, Type 2

Korea, Republic of
Aarhus University Hospital
Novo Nordisk A/S

Completed

Changes of the Infusion Rate in Insulin Pump Treatment

Diabetes

Denmark
Novo Nordisk A/S

Recruiting

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Obesity | Diabetes Mellitus, Type 2

United States, Spain, Portugal, Italy, Greece, Romania, Czechia, Slovakia, South Africa, Ukraine
Medical University of Graz

Completed

A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia

Diabetes Mellitus, Type 2

Austria
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects

Clamp Study

Russian Federation
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, South Africa, Canada
Sanofi

Completed

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day (SeLan)

Diabetes Mellitus, Type 2

Israel
Stanford University
Medtronic

Completed

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Diabetes Mellitus, Type 1

United States
University of Aarhus

Completed

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Recruiting

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2

United States, India, Spain, Poland, South Africa, Bulgaria, Germany, Japan, Puerto Rico
Yale University
Juvenile Diabetes Research Foundation

Completed

Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients

Type1diabetes

United States
Pfizer

Completed

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Puerto Rico
Sanofi

Terminated

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Diabetes Mellitus, Type 2

United States
University of Campania "Luigi Vanvitelli"

Completed

Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes

Hypoglycemia | Type 2 Diabetes Mellitus

Italy
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust; Nottingham University... and other collaborators

Completed

FASter Insulin in Closed-loop Technology in Children (FAST-Kids)

Type 1 Diabetes Mellitus

United Kingdom
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Geropharm

Unknown

Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2 | Diabetes Mellitus

Russian Federation
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Diabetes | Type 2 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico

3

Subscribe